

Evaluation Report for Category B, Subcategory 2.1, 2.3, 2.4, 2.5 Application

Application Number:	2019-2709
Application:	B.2.1: New / Changes EP or MA Product Chemistry-Guarantee
	B.2.3: New / Changes EP or MA Product Chemistry-Identity of Formulants
	B.2.4: New / Changes EP or MA Product Chemistry-Proportion of Formulants
	B.2.5: New / Changes EP or MA Product Chemistry-Formulation
	Туре
Product:	SZ-75 Herbicide
Registration Number:	33832
Active ingredients (a.i.):	Sulfentrazone
PMRA Document Number:	: 3133421

Purpose of Application

The purpose of this application was to register the end-use product, SZ-75 Herbicide, containing 75% sulfentrazone.

Chemistry Assessment

SZ-75 Herbicide is formulated as a wettable granule containing sulfentrazone at a concentration of 75%. This end-use product has a density of 0.49–0.69 g/mL and pH of 5.66–8.66. The required chemistry data for SZ-75 Herbicide have been provided, reviewed and found to be acceptable.

Health Assessments

SZ-75 Herbicide is of low acute oral and dermal toxicity and of slight inhalation toxicity in rats. It is mildly irritating to the eye of the rabbit and minimally irritating to the rabbit skin. It is not a skin sensitizer in the guinea pig.

The occupational exposure and risk from the use of this formulation of SZ-75 Herbicide label was assessed. No risks of concern are expected, provided workers follow the label directions and wear the personal protective equipment identified on the label.

Environmental Assessment

The environmental risks associated with the use of SZ-75 Herbicide are acceptable when the product is used according to the label directions.



Value Assessment

Registration of SZ-75 Herbicide will provide a new formulation of sulfentrazone to control kochia (including Group 2 and Group 9 resistant biotypes) before planting or after planting but prior to crop emergence. Addition of several tank mix partners will also help with resistance management and residual weed control.

Value information submitted for review consisted of data from replicated field trials and scientific rationales including extrapolations from registered uses. Based on the weight of evidence, the registration of SZ-75 Herbicide is supported from a value standpoint.

Conclusion

The PMRA has reviewed the information provided to support SZ-75 Herbicide. Based on the results of this review, SZ-75 Herbicide is acceptable for registration.

References

3003003	2019, Authority 75WG Herbicide Value Summary New Formulation, DACO:
	10.1,10.2,10.2.1,10.2.2,10.2.3.1,10.3,10.3.1,10.3.2
3003005	2018, Trial Title: Dry Sulfentrazone + Express SG Pre Seed, DACO: 10.2.3.3
3003006	2018, Trial Title: Dry Sulfentrazone + Express FX/DB-878 Pre Seed, DACO: 10.2.3.3
3003007	2018, Trial Title: Dry Sulfentrazone + Express Pro Pre Seed, DACO: 10.2.3.3
3003008	2018, Trial Title: Dry Sulfentrazone + Express SG Pre Seed, DACO: 10.2.3.3
3003009	2018, Trial Title: Dry Sulfentrazone + Express FX/DB-878 Pre Seed, DACO: 10.2.3.3
3003010	2018, Trial Title: Dry Sulfentrazone + Express Pro Pre Seed, DACO: 10.2.3.3
3003011	2018, Trial Title: Dry Sulfentrazone + Express SG Pre Seed, DACO: 10.2.3.3
3003012	2018, Trial Title: Dry Sulfentrazone + Express FX/DB-878 Pre Seed, DACO: 10.2.3.3
3003013	2018, Trial Title: Dry Sulfentrazone + Express FX/DB-878 Pre Seed, DACO: 10.2.3.3
	Title
PMRA #	
3003014	1994, ACUTE ORAL TOXICITY STUDY IN RATS, DACO: 4.6.1
3003022	1994, ACUTE DERMAL TOXICITY STUDY IN RATS, DACO: 4.6.2
3003023	1994, ACUTE INHLATION TOXICITY STUDY IN RATS, DACO: 4.6.3
3003024	1994, PRIMARY EYE IRRIATION STUDY IN RABBITS, DACO: 4.6.4
3003025	1994, PRIMARY SKIN IRRIATION STUDY IN RABBITS, DACO: 4.6.5
3003026	1994, SKIN SENSITIZATION STUDY IN GUINEA PIGS, DACO: 4.6.6

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2021

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.